Keywords: GlaxoSmithKline, Amicus Therapeutics, Fabry disease, Amigal, Equity stake, Research

GlaxoSmithKline expands Fabry disease deal with Amicus, upping stake in the firm

Article | 19 July 2012

Print This

Moving forward with its foray into the rare disease sector, UK pharma giant GlaxoSmithKline (LSE: GSK) and USA-based biotech firm ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in